These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26524700)

  • 1. High-Throughput Melanin-Binding Affinity and In Silico Methods to Aid in the Prediction of Drug Exposure in Ocular Tissue.
    Reilly J; Williams SL; Forster CJ; Kansara V; End P; Serrano-Wu MH
    J Pharm Sci; 2015 Dec; 104(12):3997-4001. PubMed ID: 26524700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs.
    Jakubiak P; Reutlinger M; Mattei P; Schuler F; Urtti A; Alvarez-Sánchez R
    J Med Chem; 2018 Nov; 61(22):10106-10115. PubMed ID: 30398862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of an In Vitro-In Vivo Correlation for Melanin Binding and the Extension of the Ocular Half-Life of Small-Molecule Drugs.
    Jakubiak P; Cantrill C; Urtti A; Alvarez-Sánchez R
    Mol Pharm; 2019 Dec; 16(12):4890-4901. PubMed ID: 31670965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts.
    Pelkonen L; Tengvall-Unadike U; Ruponen M; Kidron H; Del Amo EM; Reinisalo M; Urtti A
    Eur J Pharm Sci; 2017 Nov; 109():162-168. PubMed ID: 28756205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Phototoxicity Testing Strategy for Accurate Photosafety Evaluation of Pharmaceuticals Based on the Assessment of Possible Melanin-Binding Effects.
    Reinen J; van Sas P; van Huygevoort T; Rubio L; Scase K; Wenker M
    Int J Toxicol; 2018; 37(4):296-307. PubMed ID: 29898631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of affinity chromatography to the study of drug-melanin binding interactions.
    Aubry AF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 768(1):67-74. PubMed ID: 11939559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses.
    Zane PA; Brindle SD; Gause DO; O'Buck AJ; Raghavan PR; Tripp SL
    Pharm Res; 1990 Sep; 7(9):935-41. PubMed ID: 2235893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of drugs to eye melanin is not predictive of ocular toxicity.
    Leblanc B; Jezequel S; Davies T; Hanton G; Taradach C
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):124-32. PubMed ID: 9927562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity of ocular acid-insoluble melanin for drugs in vitro.
    Tsuchiya M; Hayasaka S; Mizuno K
    Invest Ophthalmol Vis Sci; 1987 May; 28(5):822-5. PubMed ID: 3570692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo models to evaluate the role of ocular melanin in trans-scleral drug delivery.
    Pescina S; Santi P; Ferrari G; Padula C; Cavallini P; Govoni P; Nicoli S
    Eur J Pharm Sci; 2012 Aug; 46(5):475-83. PubMed ID: 22484210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug accumulation in melanin: an affinity chromatographic study.
    Knörle R; Schniz E; Feuerstein TJ
    J Chromatogr B Biomed Sci Appl; 1998 Sep; 714(2):171-9. PubMed ID: 9766857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics, and Single Photon Emission Computed Tomography/Computed Tomography Imaging.
    Rimpelä AK; Schmitt M; Latonen S; Hagström M; Antopolsky M; Manzanares JA; Kidron H; Urtti A
    Mol Pharm; 2016 Sep; 13(9):2977-86. PubMed ID: 26741026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review.
    Lambrinidis G; Vallianatou T; Tsantili-Kakoulidou A
    Adv Drug Deliv Rev; 2015 Jun; 86():27-45. PubMed ID: 25819487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal pigment epithelium melanin and ocular toxicity.
    Dayhaw-Barker P
    Int J Toxicol; 2002; 21(6):451-4. PubMed ID: 12537641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic beads method for determination of binding of drugs to melanin.
    Marszałł MP; Buciński A; Goryński K; Proszowska A; Kaliszan R
    J Chromatogr A; 2011 Jan; 1218(2):229-36. PubMed ID: 21144529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Affinity of T-3761 to ocular melanin and intraocular dynamics].
    Hayakawa H; Hayashi K; Ishikura H; Nakafuku K; Takano Y; Nakajima Y; Oishi M
    Jpn J Antibiot; 1995 May; 48(5):665-70. PubMed ID: 7637201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput and in silico techniques in drug metabolism and pharmacokinetics.
    van de Waterbeemd H
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):33-43. PubMed ID: 11865671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Melanin Characteristics on Drug Binding Properties.
    Jakubiak P; Lack F; Thun J; Urtti A; Alvarez-Sánchez R
    Mol Pharm; 2019 Jun; 16(6):2549-2556. PubMed ID: 30998378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of melanin binding in ocular drug delivery.
    Rimpelä AK; Reinisalo M; Hellinen L; Grazhdankin E; Kidron H; Urtti A; Del Amo EM
    Adv Drug Deliv Rev; 2018 Feb; 126():23-43. PubMed ID: 29247767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.